Insight into the Anticancer Potential of Imidazole-Based Derivatives Targeting Receptor Tyrosine Kinases
Pharmaceuticals · 02.12.2025 · 18 (12) · 1839
DOI: 10.3390/ph18121839 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 02.12.2025. Verfasst von Sami A Al-Hussain und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU), Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University.
Abstract (Originalsprache)
Kinases, which make up 20% of the druggable genome, are thought to be essential signaling enzymes. Protein phosphorylation is induced by protein kinases. Proliferation, the cell cycle, apoptosis, motility, growth, differentiation, and other biological processes are all regulated by kinases. Their dysregulation disrupts several cellular functions, leading to a variety of illnesses, the most important of which is cancer. As a result, kinases are thought to be crucial targets in a number of malignancies and other diseases. Researchers from all over the world are hard at work developing inhibitors using various chemical structures. The scaffolds of imidazole and benzimidazole provide a versatile structure for a variety of physiologically active substances. Moreover, they serve as specialized scaffolding for the creation of target-specific pharmaceuticals to address various diseases. This article seeks to illustrate the application of imidazole and benzimidazole frameworks in the formulation of inhibitors that target various tyrosine kinases, including fibroblast growth factor receptors (FGFRs), c-Met kinase, epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), and FMS-like tyrosine kinase 3 (FLT3), from 2020 to the present. The major structure–activity correlations (SARs) of imidazole and benzimidazole derivatives were examined, and, also, a docking study highlighted the varied interactions occurring inside the active site of tyrosine protein kinases. The objective of this effort is to consolidate the fundamental structural information necessary for the synthesis of imidazole- or benzimidazole-based tyrosine kinase inhibitors with enhanced efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia.
- Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Giza 12622, Egypt.
- Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt.
- Department of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
- Department of Chemistry, Jamoum University College, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
ORCID-Profile: Thoraya A Farghaly, Magdi E A Zaki
Förderung
- the Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)
- Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University
Zitieren
APA
Al-Hussain, S. A., Dawood, D. H., Farghaly, T. A., Abu Alnjaa, A. M., & Zaki, M. E. A. (2025). Insight into the Anticancer Potential of Imidazole-Based Derivatives Targeting Receptor Tyrosine Kinases. Pharmaceuticals, 18(12), 1839. https://doi.org/10.3390/ph18121839
Vancouver
Al-Hussain SA, Dawood DH, Farghaly TA, Abu Alnjaa AM, Zaki MEA. Insight into the Anticancer Potential of Imidazole-Based Derivatives Targeting Receptor Tyrosine Kinases. Pharmaceuticals. 2025;18(12):1839. doi:10.3390/ph18121839
BibTeX
@article{AlHussain2025,
author = {Al-Hussain, Sami A and Dawood, Dina H and Farghaly, Thoraya A and Abu Alnjaa, Alaa M and Zaki, Magdi E A},
title = {Insight into the Anticancer Potential of Imidazole-Based Derivatives Targeting Receptor Tyrosine Kinases},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {12},
pages = {1839},
doi = {10.3390/ph18121839}
}
EUVIMED